Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Leading Brands Available in India for Dapagliflozin + Sitagliptin + Metformin is SITPIN DM Promoted by Edinburgh Pharmaceuticals.

Abstract

Introduction: This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET) extended release (ER) with SITA + MET sustained release (SR) and DAPA + MET ER in patients with type 2 diabetes poorly controlled with metformin.

Methods: This phase 3, randomized, open-label, active-controlled study included adult patients with glycated hemoglobin (HbA1c) ≥ 8% (64 mmol/mol) and ≤ 11% (97 mmol/mol), randomized in 1:1:1 ratio to receive either FDC of DAPA + SITA + MET ER (10 mg + 100 mg + 1000 mg) tablets once daily (n = 137) or co-administration of SITA + MET SR (100 mg + 1000 mg) tablets once daily (n = 139) or FDC of DAPA + MET ER (10 mg + 1000 mg) tablets once daily (n = 139). Primary endpoint was mean change in HbA1c from baseline to week 16.

Results: Mean baseline HbA1c was approximately 9% (75 mmol/mol) in each treatment group. At week 16, adjusted mean reduction in HbA1c from baseline was significantly greater with DAPA + SITA + MET ER (- 1.73% [- 19.0 mmol/mol]) compared to SITA + MET SR (- 1.28% [- 14.1 mmol/mol]; difference of - 0.46% [- 5.1 mmol/mol], p < 0.001) and DAPA + MET ER (- 1.33% [- 14.6 mmol/mol]; difference - 0.4% [4.4 mmol/mol], p < 0.001). Similarly, at week 12, reduction in HbA1c from baseline was significantly greater with DAPA + SITA + MET ER compared to SITA + MET SR (p = 0.0006) and DAPA + MET ER (p = 0.0276). At week 16, DAPA + SITA + MET ER showed significant reduction in postprandial blood glucose compared to DAPA + MET ER (p = 0.0394) and significant reduction in fasting blood glucose with DAPA + SITA + MET ER compared to SITA + MET SR (p = 0.0226). The proportion of patients achieving HbA1c < 7.0% (53 mmol/mol) at week 16 was significantly higher with DAPA + SITA + MET ER (38.5%) versus SITA + MET SR (12.8%) (p < 0.001) and DAPA + MET ER (21.3%) (p = 0.0023). All study medications were well tolerated.

Conclusion: Triple FDC of DAPA + SITA + MET ER tablets once daily was significantly better in achieving glycemic control versus dual combination once daily in patients with type 2 diabetes poorly controlled with metformin without any significant safety concerns.

Trial registration: CTRI/2021/11/038176, registered on 22 November 2021.

Courtesy :Rakesh K Sahay 1, Richa Giri 2, Jayashree V Shembalkar 3, Sandeep K Gupta 4, Brij Mohan 5, Prakash Kurmi 6, S Ravindra Kumar 7, Vinayak M Sawardekar 8, Ashutosh Mishra 9, L Sreenivasa Murthy 10, Vivek V Arya 11, Abhijit R Sonawane 12, Pravin N Soni 13, Sandip K Gofne 14, Shital R Karnawat 15, Mandodari N Rajurkar 16, Piyush M Patel 17, Lalit K Lakhwani 17, Suyog C Mehta 17, Sadhna J Joglekar 18

Affiliations 

• PMID: 37258803
 
• DOI: 10.1007/s12325-023-02523-z

Get More Information Click On This Website Link - www.edinburghpharma.in and QR Code

Click on Social Accounts - Facebook , LinkedIn & YouTube 

Keywords: #DPP4 inhibitor; Dapagliflozin; #Fixed-dose combination; SGLT2 inhibitor; #Type 2 diabetes , #Anti-Diabetic PCD, #Best Pharma Companies, #Top Pcd Pharma Franchise in India, #Pcd Pharma Franchise Company, #Top PCD Pharma Franchise, #Top Pharma PCD, and #Top 10 Pharma Franchise , Best PCD Pharma Franchise Company, Pharma Franchise in Uttar Pradesh, Pharma Franchise in North East.